Although increased use of immune checkpoint inhibitors and targeted therapies for B-RAF-mutant melanomas has transformed the treatment of certain metastatic melanomas, the ideal treatment for NRAS-mutant melanomas remains unknown [114]. This evidence concerns the gene BRAF and melanoma.